Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

Grants

Funding Acknowledgements

These studies were supported by funding from the National Health and Medical Research Council of Australia, Cancer Councils of Victoria and South Australia, Leukaemia Foundation of Australia, Leukemia and Lymphoma Society, Victorian Cancer Agency, Australian Cancer Research Foundation, Australian Research Council Federation, Alfred Hospital Foundation, Victorian State Government Operational Infrastructure Support, the Institut National du Cancer (PLBIO09-267), the InNaBioSante Research Foundation (RESISTAML program), and infrastructure support was provided by the Victorian Government Operational Infrastructure Support Scheme to St. Vincent's Institute. The authors thank Yang-Yen (National Taiwan University Medical School), Shaun Jackson (Australian Centre for Blood Diseases), Peter Shepherd (University of Auckland), Lorraine O'Reilley (Walter and Eliza Hall Institute), and Andrew Wilks (SYN vertical bar thesis) for reagents. The authors thank Tiffany Khong, Nathalie Gallay, Camille Fialin, Anuratha Srikumar, Daniel Gray, Andrea Reitsma, Dani Cardozo, and Estelle Saland for expert technical assistance. The authors thank Dr Cecile Demur (Collection des Hemopathies Malignes de l'INSERM Midi-Pyrenees) and Dr Andrew Spencer for patient samples and reagents. The authors thank Wallace Langdon (University of Western Australia) for critical reading of the manuscript.